- Call her savvy? Harris unleashes unconventional media blitz
- Lucian Freud 'masterpiece' fetches £13.9 million at London sale
- SoFi Stadium to hold next two CONCACAF Nations League finals
- McIlroy and DeChambeau set for PGA-LIV 'Showdown' in Vegas
- Fed minutes highlight divisions over rate cut decision
- Steve McQueen debuts new WWII film at London festival
- Run blitz edges India and South Africa closer to World Cup semi-finals
- Zelensky to court European leaders in drive for military aid
- Israel captain says 'difficult' to focus on football in time of war
- Macron to host Ukraine's Zelensky after meeting Ukrainian troops
- Root says 'many more to get' after England Test runs landmark
- India pile up World Cup high to rout Sri Lanka
- One year later, Israeli hostage family learns of loss
- Texans receiver Collins, Pats' safety Peppers out for NFL clash
- Biden-Netanyahu talk as Hezbollah, Israeli forces clash
- Musk's X available again in Brazil after 40-day ban
- Reddy stars as India crush Bangladesh to clinch T20 series
- Nobel winners hope protein work will spur 'incredible' breakthroughs
- What are proteins again? Nobel-winning chemistry explained
- Arch rivals Ghana, Nigeria drawn together in CHAN qualifying
- AI steps into science limelight with Nobel wins
- Trump lauds India's Modi as 'total killer'
- Wall Street, Europe rise as Chinese shares tumble
- Hunkering down for Hurricane Milton at Disney -- but first, a few rides
- Reddy, Rinku power India to 221-9 in second Bangladesh T20
- Overshooting 1.5C risks 'irreversible' climate impact: study
- Time running out in Florida to flee Hurricane Milton
- Demis Hassabis, from chess prodigy to Nobel-winning AI pioneer
- The long walk for water in the parched Colombian Amazon
- Biden-Netanyahu to talk as Hezbollah, Israeli forces clash
- France vows to step up drugs fight after police vehicles torched
- Air France says jet flew over Iraq during Iran attack on Israel
- Activists target Picasso work to protest Israel arms sales
- Let 'Emily in Paris' remain in Paris, Macron says
- Global stocks diverge as Chinese shares tumble
- Time runs out in Florida to flee Hurricane Milton
- Chad issues warning ahead of more devastating floods
- Record-breaking Root helps England dominate Pakistan in first Test
- German govt sees economy shrinking again in 2024
- Ex-UK soldier denies passing secrets to Iran intelligence
- Creator's death no bar to new 'Dragon Ball' products
- Three Kosovo Serbs on trial over 'secession plot' attack
- Van Gogh museum to launch Impressionism show
- French minister ups ante in Eiffel Tower Olympic rings row
- Japan PM calls snap election to 'create a new Japan'
- German police shut pro-Palestinian camp over Thunberg invite
- Chinese stocks tumble on lack of fresh stimulus
- Trio wins chemistry Nobel for protein design, prediction
- SE Asian summit urges end to Myanmar violence but struggles for solutions
- Wimbledon replaces line judges with electronic system
RBGPF | -2.48% | 59.33 | $ | |
RYCEF | -1.01% | 6.9 | $ | |
CMSD | -0.17% | 24.81 | $ | |
RIO | -0.54% | 66.3 | $ | |
CMSC | 0.04% | 24.65 | $ | |
VOD | 0.77% | 9.735 | $ | |
SCS | 1.92% | 13.03 | $ | |
NGG | -0.33% | 65.685 | $ | |
JRI | 0.34% | 13.205 | $ | |
BCC | 0.45% | 142.66 | $ | |
RELX | 0.28% | 46.77 | $ | |
BCE | -0.52% | 33.337 | $ | |
BTI | 0.71% | 35.472 | $ | |
GSK | 5.82% | 40.37 | $ | |
AZN | 0.82% | 77.505 | $ | |
BP | 0.02% | 32.035 | $ |
Pfizer drug extends life for people with rare form of lung cancer
A Pfizer lung cancer drug has been shown to greatly reduce tumor progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday.
Lorlatinib, which is already approved and available under the brand name Lorbrena in the United States, was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Roughly half received lorlatinib while the rest received crizotinib, an earlier generation drug.
After five years of follow-up, more than half of patients treated with lorlatinib did not see their cancer progress.
"We're talking about patients with advanced metastatic disease -- so this is actually a truly unprecedented finding," Pfizer's thoracic oncology strategy lead Despina Thomaidou told AFP.
Sixty percent of patients receiving lorlatinib, an oral one a day tablet, were alive without disease progression after five years compared to 8 percent on crizotinib.
"There is an 81 percent reduction in the risk of progression or death," added Thomaidou.
Lung cancer is the leading cause of cancer deaths globally.
NSCLC accounts for more than 80 percent of lung cancers, with ALK-positive tumors responsible for roughly five percent of NSCLC cases, translating to around 72,000 new cases each year worldwide.
ALK-positive NSCLC mostly affects younger patients and is not strongly linked to smoking. It is also very aggressive -- 25-40 percent of people with ALK-positive NSCLC develop brain metastases within the first two years.
Lorlatinib penetrates the blood-brain barrier better than prior generation medicines, said Thomaidou, and works to inhibit tumor mutations that drive resistance.
Patients on the lorlatinib arm had a 94 percent risk reduction in the progression of brain metastases compared to crizotinib.
Side effects of lorlatinib included swellings, weight gain and mental health problems such as depression.
"The progression-free survival is outstanding -- we have not seen anything close to this," said oncologist David Spigel of Sarah Cannon Research Institute in Nashville, who was not involved in the study.
One critique he had was that lorlatinib was compared to crizotinib, which was "an outstanding drug in its time," but has since fallen out of use in the United States.
The results were published at the annual meeting of the American Society of Clinical Oncology and in the Journal of Clinical Oncology.
P.M.Smith--AMWN